With thanks - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

With thanks


Pharmaceutical Technology Europe
Volume 21, Issue 12


Fedra Pavlou
It's the end of the year already and I hope you are looking forward to the festive period and the opportunity to wind down and spend some quality time with family and friends. I'm certainly looking forward to filling my house with too many decorations and having an excuse to over-indulge on good food and wine (I have no excuses during the rest of the year!).

I just wanted to take this opportunity to thank you for a fulfilling and eventful first year as Editor of Pharmaceutical Technology Europe (PTE). The feedback that I have received from readers and industry has proven to me that PTE is indeed a well-regarded and respected publication and I am proud to be a part of it. Thank you to everybody that has taken the time to meet with me at the various meetings that our team has attended this year; it has been a real pleasure. Thank you also to those of you who have joined our LinkedIn ( http://www.pharmtech.com/linkedin) and Twitter ( http://www.pharmtech.com/twitter) groups. It has been incredibly rewarding to see the number of members of our various networking groups growing day-by-day and to see our readers interacting with us and with each other. I also hope that you have enjoyed using our new website, which launched this summer ( http://www.pharmtech.com/). As always, I would welcome any comments that you have to make on our website and our publications, so please do feel free to email me or to post a discussion on our LinkedIn group; your opinions are of the utmost importance to me and to the rest of the PTE team.

I would now like to take this opportunity to wish you happy holidays and to thank you for your continued support of our publication throughout the year. Let's look forward to a happy and successful 2010!

Best wishes,
Fedra Pavlou
Editor-in-Chief

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology Europe,
Click here